RCM
XLRN

RA Capital Management’s Acceleron Pharma XLRN Stock Holding History

RA Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-318,565
Closed -$11.5M – 36
2016
Q3 		$11.5M Buy
+318,565
New +$10.6M 1.19% 21

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

RA Capital Management's XLRN Position: Q4 2016 in Review

RA Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2016, closing a stake of 318,565 shares — an estimated $11.5M sold.

RA Capital Management first reported a position in XLRN in Q3 2016 and held it in 1 quarter. The position peaked at $11.5M in Q3 2016. 146 funds tracked by Wall St. Rank hold XLRN as of Q4 2016.

  • RA Capital Management reported no remaining Acceleron Pharma position as of Q4 2016 after selling out during the quarter.
  • RA Capital Management sold 318,565 Acceleron Pharma shares in Q4 2016, an estimated $11.5M.
  • RA Capital Management first reported a position in Acceleron Pharma in Q3 2016 and held it in 1 quarter.
  • RA Capital Management's Acceleron Pharma position peaked at $11.5M in Q3 2016.
  • 146 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2016.

Based on RA Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.